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Genetic alterations affecting members of the Janus kinase (JAK) family have been discovered in a wide array
of cancers and are particularly prominent in hematological malignancies. In this review, we focus on the role
of such lesions in both myeloid and lymphoid tumors. Oncogenic JAK molecules can activate a myriad of
canonical downstream signaling pathways as well as directly interact with chromatin in noncanonical
processes, the interplay of which results in a plethora of diverse biological consequences. Deciphering these
complexities is shedding unexpected light on fundamental cellular mechanisms andwill also be important for
improved diagnosis, identification of new therapeutic targets, and the development of stratified approaches
to therapy.Mature blood cells are predominantly short-lived, with more than
53 1011 cells turned over each day during steady state hemato-
poiesis. The continual replenishment of blood cells is the
mandate of the hematopoietic stem cells (HSCs), which display
both self-renewal capacity and the ability to differentiate into
mature cells of the blood, such as erythrocytes, megakaryo-
cytes, neutrophils, and lymphocytes. Hematopoiesis is a hierar-
chical process in which HSCs reside at the apex of a hierarchy of
multilineage and unilineage progenitors of increasingly restricted
potential that can ultimately develop into terminally differenti-
ated, specialized blood cells. Homeostasis is ensured by intri-
cate mechanisms that integrate differentiation, proliferation,
and cell death, with disruption of these checks and balances
leading to oncogenic consequences.
Cytokines play a critical role during hematopoietic ontogeny
by initiating intracellular signals that govern cell fate choices
such as proliferation and differentiation. Most cytokine receptors
lack intrinsic kinase activity, and hence often employ Janus
kinases (JAKs) as signaling intermediates to facilitate down-
stream signaling. JAKs are a family of four nonreceptor tyrosine
kinases (JAK1, JAK2, JAK3, and TYK2), which are generally
found constitutively bound to receptors and which are activated
after cytokine receptor activation. JAK activation results in phos-
phorylation of the STAT transcription factors, of which seven
members exist (STAT1, STAT2, STAT3, STAT4, STAT5A,
STAT5B, and STAT6). Upon activation, STAT complexes trans-
locate into the nucleus, bind DNA, and initiate transcription.
The critical roles of JAK and STAT proteins in hematopoietic
ontogeny have been clearly demonstrated via targeted gene
disruption studies in mice (reviewed by Khwaja, 2006). Loss of
Jak1, Jak3, or Tyk2 results in impaired lymphopoiesis whereas
Jak2deficiency results in embryonic lethality asa result of a failure
of definitive erythropoiesis. These phenotypes largely reflect
defects in specific cytokine signaling pathways within which
JAK family members play key roles. Mice lacking Stat1, Stat2,
Stat4, or Stat6 are viable but exhibit specific signaling abnormal-
ities, predominantly in lymphoid cells. Stat3 deficiency results in
early embryonic lethality as a result of severe developmental
defects, and simultaneous loss of both Stat5a and Stat5b leadsto perinatal lethality with anemia and leucopenia. Most studies
have not distinguished between Stat5a and Stat5b and so the
term ‘‘Stat5’’ will be used to represent their combined effects.
In many chronic and acute hematological malignancies,
acquired genetic lesions cause aberrant JAK-STAT signaling.
Neoplastic modulation of JAK-STAT pathways may be indirect
and result from mutations that activate upstream receptors
such as the Flt3-ITD mutation in acute myeloid leukemia (AML)
or from activation of other signaling proteins such as the BCR-
ABL protein in chronic myeloid leukemia (CML). Due to space
limitations, these types of lesions will not be discussed in detail
here. Instead, we will focus on genetic alterations that directly
target components of the JAK-STAT pathway (Figure 1, Table 1).
JAK2 Mutations in Chronic Myeloid Malignancies
Mutations of JAK family members recently came to prominence
with the discovery of the V617F mutation in JAK2 in a substantial
proportion of patients with chronic myeloproliferative neoplasms
(MPNs) (Baxter et al., 2005; James et al., 2005; Kralovics et al.,
2005; Levine et al., 2005b). MPNs encompass a spectrum of
neoplastic disorders characterized by overproduction of termi-
nally differentiated cells of the myelo-erythroid lineage and share
a predisposition to the development of AML. The JAK2-V617F
mutation was detected in95%of individuals with polycythemia
vera (PV) and 50%-60% of those with essential thrombocythe-
mia (ET) and primary myelofibrosis (PMF). Subclones homozy-
gous for the JAK2-V617F mutation are readily detectable in
most patients with PV but are undetectable or present at a low
level in most patients with ET (Scott et al., 2006). The V617F
mutation is also detectable at lower frequencies in other chronic
myeloid malignancies including systemic mastocytosis (6%),
chronic myelomonocytic leukemia (6%), Philadelphia-negative
CML (19%), myelodysplastic syndrome (MDS) (3%), and refrac-
tory anemia with ringed sideroblasts associated with thrombo-
cytosis (RARS-T) (50%) (Jelinek et al., 2005; Jones et al.,
2005; Levine et al., 2005a; Scott et al., 2005; Steensma et al.,
2005). PV patients negative for JAK2-V617F often harbor one
of several mutations in exon 12 of JAK2, a finding that revealed
the existence of a previously unrecognized a PV subtypeImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 529
1 1132
111984980554548238627038
1 1124
109582277752148536220139
V617F
L611S
D873N
ΔIREED
R683G
R683S
R683K
R682
A634D
P933R
exon12
mutations
T478S
V623A
S512L V658F
R724H
R724Q
R879S
R879C
R879H
A572V V722IP132T
MPN mutations
AML mutations
B-lineage ALL mutations
JAK3
R867Q
T-ALL mutations
AMKL mutations
1 1154
114787584558352742628637
JAK1
JAK2
ATLL mutations
L156P
R172Q
E183G
Figure 1. Summary of JAK Mutations
Discovered in Hematological Malignancies
Color-coded representation of the location of
each mutant residue within the domain structure
of each JAK protein. The majority of mutations in
JAK proteins are found within the pseudokinase or
kinase domain.
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Reviewassociated with a more isolated erythrocytosis (Scott et al.,
2007). Additional rare variants in exons 12 to 15 have been iden-
tified (Ma et al., 2009).
Genetic predisposition to the development of an MPN is
increasingly recognized. Large population studies of first-degree
relatives of MPN patients have revealed a 5- to 7-fold increase in
the risk of developing an MPN (Landgren et al., 2008). A haplo-
type block called ‘‘46/1’’ or ‘‘CCGG,’’ and which contains the
JAK2 gene itself, has been reported by several groups to
increase the odds of developing an MPN by 3- to 4-fold (Jones
et al., 2009; Kilpivaara et al., 2009; Olcaydu et al., 2009). The
46/1 haplotype occurs predominantly in ciswith the V617Fmuta-
tion and is thought to be in linkage disequilibriumwith a locus that
either increases the occurrence of JAK2 mutations or provides
a selective advantage for JAK2mutations once they have arisen.
The V617F and exon 12 mutations are located within the JAK2
JH2 pseudokinase domain and normally inhibit the adjacent JH1
tyrosine kinase domain (Giordanetto and Kroemer, 2002). The
mutations are predicted to be located at the JH1-JH2 interface
and are thought to abrogate the JH2 inhibitory effect, thus result-
ing in dysregulated JAK2 kinase activity. A crystal structure of
the JAK2 JH1 tyrosine kinase domain has been reported (Lucet
et al., 2006) but none are available for the full-length protein or for
a fragment containing both JH1 and JH2 domains, and so the
details of the JH1-JH2 interaction remain unclear. However,
recent data have provided some clues. It has been suggested
that optimal activation of JAK2-V617F requires an aromatic
amino acid at residue F595 to mediate a stacking interaction530 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.with the mutant F617 within the JH2 aC
helix (Dusa et al., 2010). It has also been
reported that the JH2 domain possesses
low-level dual-specific kinase activity
that is required for autophosphorylation
at residues S523 and Y570, two modifi-
cations thought to be important for
facilitating JH1-JH2 interaction and
maintaining JAK2 in an inactive state (Un-
gureanu et al., 2011). According to this
model, the V617F mutation abrogates
the dual-specific kinase activity of the
JH2 domain, resulting in diminished
phosphorylation of S523 and Y570 and
consequently dysregulated JH1 tyrosine
kinase activity.
JAK Mutations in Acute Leukemias
In contrast to the morphologically normal
hematopoietic differentiation that typifies
chronic neoplasms, acute myeloid leuke-
mias (AML) and acute lymphoblasticleukemias (ALL) are characterized by a differentiation block
with accumulation of primitive blast cells in the bone marrow
and/or peripheral blood. Acquired lesions involving JAK1,
JAK2, and JAK3 (but not TYK2) have been reported in both
AML and ALL.
Historically, acute leukemias were the first malignancies to be
associated with a lesion in a JAK gene. The TEL-JAK2 fusion
protein was originally observed as the gene product of a
t(9;12)(p24;p13) translocation in a patient with T-ALL (Lacronique
et al., 1997). The chimeric protein contains the oligomerization
domain of the Ets protein TEL and the JH1 tyrosine kinase
domain of JAK2. The TEL subunit facilitates homodimerization
of TEL-JAK2 molecules, thus facilitating transphosphorylation
and activation of the JAK2 kinase domains. Several analogous
JAK2 fusion proteins have since been described in ALLs or
AMLs, including PCM1-JAK2 (Reiter et al., 2005), BCR-JAK2
(Griesinger et al., 2005), RPN1-JAK2 (Mark et al., 2006),
SSBP2-JAK2 (Poitras et al., 2008), and PAX5-JAK2 (Nebral
et al., 2009). In all cases, the mechanism of JAK2 activation is
thought to be similar, with the JAK2 fusion partner promoting
dimerization and constitutive activation of the JAK2 tyrosine
kinase component of the fusion protein. Detailed biochemical
analyses of most of these fusion gene products have yet to be
reported.
In recent years, point mutations that activate JAK family
members have also been revealed to be a common in acute
leukemias. Multiple different JAK2 mutations have been re-
ported. The JAK2-V617F mutation is found in 3%–5% of
Table 1. JAK-Related Mutations in Hematological Malignancies
Type of Lesion Mutation Disease Frequency Reference
Fusion TEL-JAK2 T-ALL rare Lacronique et al. (1997)
BCR-JAK2 atypical CML rare Griesinger et al. (2005)
PCM1-JAK2 AML, T-ALL rare Reiter et al. (2005)
RPN1-JAK2 PMF rare Mark et al. (2006)
SSBP2-JAK2 B-ALL rare Poitras et al. (2008)
PAX5-JAK2 B-ALL rare Nebral et al. (2009)
Point Mutation: JAK2 V617F PV 95% Baxter et al. (2005); James et al. (2005);
Kralovics et al. (2005); Levine et al. (2005b)
ET 50%–60% see above
PMF 50%–60% see above
exon 12 variants PV 3% Scott et al. (2007)
exon 12-15 variants MPNs rare Ma et al. (2009)
DIREED B-ALL rare Malinge et al. (2007)
L611S B-ALL rare Kratz et al. (2006)
R683 variants DS-ALL 18%–28% Bercovich et al. (2008); Kearney et al. (2009)
R683 variants B-ALL 7% Mullighan et al. (2009b)
Point Mutation: JAK1 T478S, V623A AML rare Xiang et al. (2008)
A634D T-ALL 4%–18% Asnafi et al. (2010); Flex et al. (2008)
Point Mutation: JAK3 A572V, V722I, P132T AMKL rare Walters et al. (2006)
L156P, R172Q, E183G ATLL rare Elliott et al. (2011)
Amplification JAK2 PMBL, HL 30%–50% Joos et al. (2000); Lenz et al. (2008);
Rosenwald et al. (2003)
Disease abbreviations are as follows: T-ALL, T cell acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; AML, acute myelogenous
leukemia; B-ALL, B lineage acute lymphoblastic leukemia; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis;
MPN, myeloproliferative neoplasms; DS-ALL, Down’s syndrome-associated acute lymphoblastic leukemias; AMKL, acute megakaryocytic leukemia;
ATLL, adult T cell leukemia or lymphoma; PMBL, peripheral mediastinal B cell lymphoma; HL, Hodgkin’s lymphoma.
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Reviewde novo AMLs (Scott et al., 2005; Steensma et al., 2005), but at
least some of these cases may represent transformation from an
undiagnosed prior MPN. Several groups have also identified
additional JAK2 mutations in 18%–28% of B progenitor ALLs
that develop from Down’s syndrome patients (DS-ALL) (Berco-
vich et al., 2008; Kearney et al., 2009) and in 7%of high-risk pedi-
atric B lineage ALL patients with or without Down’s syndrome
(Mullighan et al., 2009b). Multiple mutations were found near
the R683 residue, of which JAK2-R683G was the most common.
In silico structure modeling of JAK2 predicts that the R683
residue resides within a deep and narrow binding pocket within
the pseudokinse domain and forms a salt bridge with E685 (Ber-
covich et al., 2008). Mutation of R683 probably interferes with the
formation of the salt bridge and changes the physicochemical
properties of the binding pocket, potentially altering the capacity
of the JH2 pseudokinase domain to undergo intramolecular or
intermolecular interaction. At present, it is unclear whether the
R683 mutations function to disrupt autoinhibition in the same
way postulated for the archetypal V617F mutation. Whereas
V617 is predicted to be situated at the interface between the
pseudokinase and kinase domains, R683 is predicted to be
located in a different region of the pseudokinase domain (Berco-
vich et al., 2008). Finally, three additional mutations within the
catalytic tyrosine kinase domain of JAK2 were identified in B
lineage ALL patients (Mullighan et al., 2009b), although func-
tional characterization has yet to be performed.JAK1 mutations have been reported in 4%–18% of T-ALLs
(Asnafi et al., 2010; Flex et al., 2008), in 3% of poor-prognosis
pediatric B lineage ALL patients (Mullighan et al., 2009b), and
in 2% of de novo AMLs (Xiang et al., 2008). The majority of
these mutations occurred within the pseudokinase domain.
Indeed, the oncogenic potential of pseudokinase domain
disruption within JAK1 had been predicted earlier by studies
in which introduction of a V658F mutation in JAK1 (homologous
to the V617F mutation in JAK2) led to its constitutive activation
(Staerk et al., 2005). At least one of the JAK1 mutations may act
in a similar manner as indicated by the fact that in silico struc-
tural modeling of the JAK1-A634D mutant predicted the
mutated amino acid residue to reside on a surface of the pseu-
dokinase domain that directly interacts with the kinase domain
(Flex et al., 2008).
JAK3 mutations in ALL and AML are rare. However, several
nonrecurrent JAK3 mutations were identified in the CMK mega-
karyoblastic cell line and patients with acute megakaryoblastic
leukemia (AMKL) (Walters et al., 2006). All three mutations
were found to constitutively activate the JAK3 protein, although
only the A572V and V722I mutants are situated within the pseu-
dokinase domain. A P132T mutation lies within the receptor
binding region of JAK3 and the mechanism by which it activates
JAK3 is not clear. Several different JAK3 mutations have since
been reported in primary AMKL samples but are yet to be func-
tionally characterized (Malinge et al., 2008; Sato et al., 2008).Immunity 36, April 20, 2012 ª2012 Elsevier Inc. 531
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Given the importance of JAK-STAT signaling in normal mature
lymphoid subpopulations, it is not surprising that many lymphoid
malignancies derived from these normal cells coopt these path-
ways to aid and abet their oncogenic missions. Although histo-
logically very distinct, Hodgkin lymphoma (HL) and peripheral
mediastinal B cell lymphoma (PMBL) share a common gene
expression signature that distinguishes them from other aggres-
sive lymphoma subtypes (Rosenwald et al., 2003; Savage et al.,
2003). The PMBL and HL signatures stem from the action of
JAK2 signaling, which is a feature of both lymphoma subtypes,
and cell line models of PMBL and HL die when JAK2 is geneti-
cally or pharmacologically inhibited (Rui et al., 2010). The
underlying genetic basis for these observations is the recurrent
amplicon involving JAK2 on chromosome band 9p24 seen in
30%–50% of HL and PMBL cases (Joos et al., 2000; Lenz
et al., 2008; Rosenwald et al., 2003). The minimally amplified
region is 3 Mb and includes not only JAK2 but also several
other functionally interesting genes including JMJD2C and
RANBP6. These three genes are coordinately overexpressed in
a significant proportion of HL and PMBL where they function in
concert to promote lymphomagenesis (discussed below).
Cell of Origin and Mutation Timing
MPNs represent a particularly attractive model in which to study
cancer development. In the chronic phase, they are thought to
represent a very early stage of tumor evolution inaccessible in
most cancers, because many patients are diagnosed early after
an incidental blood count, the neoplastic clone has not acquired
lesions resulting in a differentiation block, and there is usually no
overgrowth of a dominant clone as found in most acute malig-
nancies. MPNs tend to evolve from a chronic phase to a more
aggressive accelerated phase or to overt AML over a period of
many years, thus allowing studies of disease evolution. Of partic-
ular note, clonal analysis can be performed by studying colonies
grown in vitro from single progenitor cells.
Initial studies using X chromosome inactivation in MPN
patients suggested the HSC as the cell of origin of MPNs (re-
viewed in Chen and Prchal, 2007). Subsequent to the discovery
of the JAK2-V617F mutation, testing for its presence in different
hematopoietic compartments was performed to determine the
cell in which the mutation arose. The disease allele was detected
in multipotent HSC subpopulations in PV and PMF patients (Ja-
mieson et al., 2006), LTC-ICs derived from bone marrow of MPN
patients (James et al., 2008), and long-term engrafted cells in
NOD-SCID mice transplanted with CD34+ cells from MPN
patients (Ishii et al., 2007). Cumulatively, the above data sug-
gested that the JAK2-V617F mutation is present in a cell exhibit-
ing HSC-like properties. However, it is also formally possible
that the JAK2-V617F mutation arises in a myeloid progenitor
cell that subsequently acquires properties of self-renewal and
the capacity to undergo multipotential differentiation. Indeed,
stochastic mathematical modeling studying the evolutionary
dynamics of cancer-initiating cells predicts this path to MPN
development to be the most likely (Haeno et al., 2009).
Whether it arises in the HSC or multipotent progenitor com-
partment, the JAK2-V617F mutation will be carried by differenti-
ated progeny in multiple lineages and will therefore potentially
influence the behavior of multiple different cell types. Addition-532 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.ally, terminally differentiated mature cells also have the ability to
influence the behavior of stem and progenitor cells, thus further
complicating the biological consequences of this single muta-
tion. Studies of knockin mice engineered to express physiolog-
ical levels of JAK2-V617F suggest that the mutant JAK2 imparts
little or no selective advantage at the HSC level. Compared to
wild-type HSCs, JAK2-V617F-positive HSCs show either no
advantage (Mullally et al., 2010) or a disadvantage (Li et al.,
2010b) in murine competitive transplantation assays. This is
consistent with several additional lines of evidence suggesting
that JAK2-V617F exerts little effect on HSC self-renewal
capacity: (1) xenograft transplantation of MPN HSCs into SCID
immunodeficient mice demonstrated successful engraftment
of V617F-positive HSCs but no obvious selective advantage
compared to normal HSCs (James et al., 2008); (2) in a case in
which a patient with high-risk MDS was transplanted with
V617F-positive allogeneic donor cells, the recipient remained in
remission and exhibited no increase in V617F allele burden for
at least 7 years posttransplant (VanPelt et al., 2008); and (3) retro-
viral studies in mice have shown that expression of constitutively
activated tyrosine kinases (e.g., BCR-ABL, FLT3-ITD) does not
trigger self-renewal in recipient cells (Huntly et al., 2004).
In contrast, JAK2-V617F has been suggested to play key roles
in later stages of myelopoiesis. Progenitor cells from MPN
patients form erythroid or megakaryocytic colonies in the
absence of exogenous growth factors, a phenomenon thought
to be a direct consequence of mutant JAK activity. The increase
in erythropoiesis observed in patients with PV is likely to reflect
an effect of JAK2 activation on the late stages of erythroid
differentiation, although the detailed cell biology has yet to be
elucidated, and it also remains unclear why the consequences
of mutant JAK2 are different in patients with ET. Consistent
with this idea that mutant JAK2 acts at multiple levels within
hematopoiesis, JAK2-V617F gene-targeted mice display expan-
sion of lineage-restricted myeloid compartments, increased
numbers of BFU-E, CFU-GM, and CFU-Megs, together with
increased erythroid and megakaryocytic terminal differentiation
(Li et al., 2010b; Mullally et al., 2010).
Whether JAK2-V617F represents the initiating lesion in MPNs
remains a topic of intense investigation. Its involvement in an
example of an early-stage cancer like the MPNs implies that it
might have an initiating role. In addition, retroviral transduction-
based and transgenic mouse studies showed that JAK2-V617F
was sufficient to generate a myeloproliferative phenotype (re-
viewed in Li et al., 2011). This was corroborated by knockin
mouse studies in which transplantable MPN phenotypes ranging
from thombocytosis to polycythemia were also observed (Li
et al., 2010b; Mullally et al., 2010). However, some caveats
should be considered when evaluating these data. Retroviral
and transgenicmodels often result in dysregulation of the pattern
or level of expression of mutant JAK2, and even in knockin
models, JAK2 is still activated simultaneously in large numbers
of hematopoietic cells. This contrasts with the monoclonal origin
of human malignancies. Indeed, several lines of evidence
suggest that, in some patients, JAK2-V617F is not the initiating
lesion. Secondary AMLs arising from a V617F-positive MPN
are often wild-type for the JAK2 allele (Beer et al., 2010; Camp-
bell et al., 2006; Theocharides et al., 2007), a finding that led to
the concept that these individuals harbored (at least) two distinct
Immunity
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mutation. This notion of oligoclonality in some MPN patients is
consistent with the observations that some patients possess
granulocyte clonality in excess of the V617F allelic burden (Kra-
lovics et al., 2006) and the existence of erythropoietin-indepen-
dent erythroid colonies (EECs) that are negative for the JAK2
mutation in patients with a JAK2-V617F-positive MPN (Nussenz-
veig et al., 2007).
Definitive support for the presence of genetically distinct
clones has come from studies of clonally derived hematopoietic
colonies and the demonstration that individual colonies can
carry mutually exclusive acquired genetic lesions. The presence
of biclonal disease could reflect the existence of a shared
founder clone, evidence for which has come from the demon-
stration that TET2 mutations (Beer et al., 2009; Delhommeau
et al., 2009) or 20q deletion (Schaub et al., 2009) can precede
acquisition of the JAK2 mutation. Of particular interest, X chro-
mosome inactivation studies have demonstrated that biclonal
disease can also reflect independent expansions arising from
unrelated HSCs, a situation reported in two of three evaluable
patients (Beer et al., 2009).
In summary, by exploiting the JAK2-V617F-positive preleuke-
mic MPNs as an experimentally tractable system, significant
insights have been gained into the underlying biology of blood
cancer development at its earliest stages.
Mutant JAKs and Receptors
One of the distinguishing hallmarks of gain-of-function JAK
mutations is their ability to confer cytokine-independent growth
and survival when introduced into cytokine-dependent cell lines.
For example, TEL-JAK2 homodimers in the cytosol leads to
STAT5 activation without a requirement for cytokine stimulation
(Lacronique et al., 2000) and expression of JAK2-V617F in BaF3
cells causes factor independent growth and survival, associated
with increased JAK2 phosphorylation and STAT5 activation
(James et al., 2005; Kralovics et al., 2005; Levine et al., 2005b).
The ability of JAK2-V617F to produce factor-independent
growth has been reported to require the presence of homodi-
meric type I receptors, which is thought to act as a scaffold
that juxtaposes two JAK2 molecules and facilitates transphos-
phorylation (Lu et al., 2005).
The ALL-associated JAK2-R683G mutant also requires the
presence of cytokine receptors. In 50%–60% of B lineage ALL
patients, leukemic blasts exhibit increased cell surface expres-
sion of the cytokine receptor-like factor 2 (CRLF2) (Mullighan
et al., 2009a; Russell et al., 2009). CRLF2 is a JAK2-binding cyto-
kine receptor subunit that, together with IL-7Ra, forms the heter-
odimeric thymic stromal lymphopoietin (TSLP) receptor.
Increased expression of CRLF2 in B lineage ALLs is achieved
in two ways: (1) through an interstitial deletion within the X chro-
mosome that brings the CRLF2 gene under the control of the
P2RY8 promoter, or (2) chromosome translocations that place
the CRLF2 gene under the control of the IGH promoter (Mul-
lighan et al., 2009a). Illegitimate recombination involving a pseu-
doautosomal region adjacent to theCRLF2 gene is thought to be
responsible for the formation of both lesions (Mullighan et al.,
2009a). JAK2mutations have been found in 34%ofCRLF2-over-
expressing DS-ALL patients (Mullighan et al., 2009b) and 69% of
patients with high-risk pediatric B lineage ALL with CRLF2 rear-rangements (Harvey et al., 2010a) but are uncommon in those
lacking CRLF2 overexpression or rearrangements. This strong
association suggests functional cooperativity and, consistent
with this, JAK2-R683G and CRLF2 proteins interact and their
coexpression is necessary for cytokine-independent growth of
BaF3 cells (Mullighan et al., 2009a; Yoda et al., 2010).
JAK1 mutants seen in T-ALL and B lineage ALL have been re-
ported to be capable of transforming Ba/F3 cells to factor inde-
pendence without coexpression of a receptor (Flex et al., 2008).
It is unclear whether this difference from JAK2 mutants is due
to a true biological peculiarity of the JAK1 mutants or whether it
reflects issues of experimental methodology such as the level
of mutant JAK1 expression achieved. In addition, BaF3 cells
are lymphoid and so may possess a repertoire of endogenous
receptors that are able to provide scaffolding for mutant JAK1
molecules. It seems inherently unlikely that receptors do not
play a role in mutant JAK1 signaling, and consistent with this,
mutating the FERM domain, thus preventing receptor binding,
abolished the activation and transforming ability of JAK1-V658F
(Hornakova et al., 2009). A clue into the potential scaffold for
mutant JAK1 molecules came with the recent identification of
activating mutations in the a subunit of the IL-7 receptor
(IL-7Ra) that stimulates a JAK1-STAT5 signaling axis to induce
transformation in approximately 10% of T-ALLs (Shochat et al.,
2011; Zenatti et al., 2011).
JAK2-V617F mutations are observed only in myeloid disor-
ders, whereas JAK2-R683G and JAK1 mutations are seen in
ALLs and not MPNs. These striking disease associations remain
poorly understood, but it seems likely that distinct JAK family
mutations require different cellular contexts to exert their
neoplastic functions, with particular mutations requiring the
presence of specific cytokine receptors.
Canonical Effects of Mutant JAK Signaling
The canonical downstream signaling consequences of JAK
mutations have been best studied in the context of JAK2 muta-
tions. As discussed above, JAK2 is involved in signaling from
multiple cytokine receptors. In addition, it is capable of activating
multiple STATs, as well as the PI3K and the MAPK signaling
pathways. The transcriptional programs activated by mutant
JAK2 in a given cell type will therefore depend on the comple-
ment of receptors, STATs, and other signaling pathway compo-
nents present in that cellular context (Figure 2). In the following
sections, we will review the role of these canonical signaling
pathways in the pathogenesis of various hematological disor-
ders associated with mutant JAK signaling.
STAT5
Most is known about STAT5 and its role downstream of mutant
JAK2. Neither TEL-JAK2 nor JAK2-V617F is capable of pro-
ducing disease in a Stat5-deficient background (Funakoshi-
Tago et al., 2010; Walz et al., 2012; Yan et al., 2011a), and
mice reconstituted with bonemarrow expressing a constitutively
active Stat5a mutant develop a fatal myeloproliferative syn-
drome (Schwaller et al., 2000). Moreover, overexpression of
Stat5 in the lymphoid compartment can also give rise to thymic
T cell lymphoblastic lymphoma inmice (Kelly et al., 2003). Cumu-
latively, these data suggest that STAT5 is necessary for hemato-
logical disease downstream of mutant JAKs, and also that itsImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 533
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Figure 2. Signaling Complexities of Janus
Kinases
Janus kinases (JAKs) such as JAK2 can modulate
signaling through multiple different cytokine
receptor families, and can activate multiple
downstream canonical pathways such as STATs,
PI3K and ERK, as well as non-canonical pathways
via direct nuclear targeting. The biological con-
sequences elicited by oncogenic JAK signaling
will therefore depend on the complement of
receptors, STATs and other signaling pathway
components present in that cellular context.
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Reviewactivation is sufficient to generate a malignant phenotype when
overexpressed. STAT5 activates large numbers of targets with
at least three subcategories likely to relate to oncogenesis: (1)
cell cycle regulators, such as the D-type cyclins, MYC, and
PIM1 (Matsumura et al., 1999); (2) DNA repair proteins, such as
RAD51 and DNA polymerase b (Slupianek et al., 2002)—this
may contribute to the augmentation of error-prone DNA repair
that has been reported in some MPN patients (Plo et al., 2008),
and thus, could contribute to a degree of genomic instability;
and (3) antiapoptotic proteins such as BCL-XL and BCL-2
(Dumon et al., 1999). BCL-XL overexpression is able to mimic
some features of mutant JAK2 expression, including cytokine-
independent growth and EEC formation (Garc¸on et al., 2006).
In the presence of DNA damage, BCL-XL undergoes deamida-
tion and, as a consequence, apoptosis is enhanced in normal
cells. However, in primary cells from MPN patients, mutant
JAK2 blocks DNA damaged-induced deamidation of BCL-XL534 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.and therefore promotes the accumula-
tion of cells harboring DNA damage,
thus providing a mechanism for disease
evolution (Zhao et al., 2008).
STAT3
Although STAT3 is a well-known onco-
gene in the context of both solid and
hematological malignancies, the role of
JAK-STAT3 signaling in the pathogenesis
of myeloid disorders remains unclear.
Higher amounts of tyrosine-phosphory-
lated STAT3 have been reported in gran-
ulocytes of some JAK2-V617F-positive
MPN patients and are associated with
heightened resistance to apoptosis
caused by cytokine withdrawal (Mesa
et al., 2006), although others have failed
to see this correlation (Teofili et al.,
2007). Recentmurine studies have shown
Stat3 to be dispensable for myeloid
expansion induced by JAK2-V617F (Yan
et al., 2011a). Further studies will be
required to clarify the role of STAT3 in
myeloid malignancies.
In contrast, emerging evidence is impli-
catingaprominent role for increasedJAK-
STAT3 signaling during lymphomagene-
sis. In the activated B cell-like (ABC)
subtype of diffuse large B cell lymphoma(DLBCL), approximately half of all tumors exhibit a STAT3 gene
expression signature (Figure 3, top; Ding et al., 2008; Lam et al.,
2008). The underlying genetic basis for constitutive JAK-STAT3
signaling in ABC DLBCL was illuminated by the discovery of
mutations in the TIR domain of MYD88, a key adaptor in Toll-
like receptor signaling (Ngo et al., 2011). Overall, 39% of ABC
DLBCL tumors haveMYD88mutations, includingmany recurrent
point mutations indicative of selection. However, one mutant,
termed L265P, is the clear evolutionary winner, occurring in
29% of ABC DLBCL cases but only rarely among other aggres-
sive lymphoma subtypes. MYD88-L265P mutations are also
frequent among primary central nervous system lymphomas,
chronic lymphocytic leukemia, and marginal zone lymphomas
(Ngo et al., 2011; Yan et al., 2011b).
These gain-of-functionMYD88mutations activate JAK-STAT3
signaling in an autocrinemanner. The biochemical mechanism of
action of MYD88 mutants involves the recruitment of the kinases
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Figure 3. JAK-STAT Signaling in Lymphomas
Top: Autocrine JAK-STAT3 signaling in activated B cell like diffuse large B cell
lymphoma. MYD88 mutants activate NF-kB and p38 MAP kinase signaling
pathways to increase production and secretion of IL-6 and IL-10, which in turn
activate the JAK-STAT3 pathway by autocrine stimulation of their respective
receptors. MYD88 mutants can also activate type I interferon pathways
through increased production of IFN-b. Bottom, Molecular consequences of
9p24 amplification in Hodgkin lymphoma and primary mediastinal B cell
lymphoma. Increased expression of JAK2 and JMJD2C following 9p24
amplification synergizes to destabilize heterochromatic state and positively
regulate expression of multiple genes (such as those encoding MYC, JAK2,
JMJD2C, IL4RA, PD-L1, and PD-L2) that promote increased growth factor
signaling, immune suppression and proliferation.
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ReviewIRAK4 and IRAK1 into a constitutive signaling complex in which
IRAK1 is phosphorylated by IRAK4 (Ngo et al., 2011). Phosphor-
ylation of IRAK1 engages the NF-kB and p38 MAP kinase
signaling pathways, which coordinately induce the expression
of the cytokines IL-6 and IL-10, which in turn activate the JAK-
STAT3 pathway by autocrine stimulation of their respective
receptors (Lam et al., 2008; Ngo et al., 2011). STAT3 also phys-
ically interacts with NF-kB p50-p65 heterodimers to potentiate
transactivation of NF-kB target genes (Yang et al., 2007).
A likely consequence of this regulatory cooperation is high rela-
tive expression of a set of NF-kB target genes in STAT3+ ABC
DLBCL tumors (Lam et al., 2008). STAT3-NF-kB cooperation
may also account for the fact that JAK-STAT3 signaling canpromote secretion of IL-6 and IL-10, both of which are NF-kB
targets (Lam et al., 2008).
The MYD88-dependent JAK-STAT3 signaling in ABC DLBCLs
suggests several therapeutic strategies. A small molecule pan-
JAK kinase inhibitor induces apoptosis in ABC DLBCL cell lines
but has little if any effect on cell linemodels of the germinal center
B cell-like (GCB) DLBCL subtype (Lam et al., 2008). Likewise,
genetic or pharmacologic inhibition of STAT3 is toxic for ABC
DLBCL cell lines (Scuto et al., 2011). Inhibitors of IkB kinase
(IKK), which block NF-kB signaling, also induce apoptosis in
ABC DLBCL cell lines (Lam et al., 2005). Combined treatment
with JAK kinase and IKK inhibitors is synergistically toxic for
ABC DLBCL cell lines, possibly as a result of the cooperation
between STAT3 and NF-kB mentioned above (Lam et al.,
2008). JAK inhibitors emerge from these studies as viable thera-
peutic candidates in ABC DLBCL that could be combined with
other drugs that block constitutive NF-kB signaling. In addition,
a small molecule inhibitor of IRAK4 kinase was selectively toxic
for ABC DLBCL cell lines bearing the MYD88-L265P mutant
(Ngo et al., 2011). IRAK4 kinase inhibitors, which are in clinical
development for a variety of inflammatory and autoimmune
diseases, could be repurposed to shut down MYD88 signaling
in ABC DLBCL.
STAT1
JAK proteins also play pivotal roles in both type I and type II inter-
feron signaling, and unsurprisingly, expression of constitutively
active JAK molecules in cell line models can directly activate
interferon signaling pathways via the direct phosphorylation of
STAT1 (Chen et al., 2010; Xiang et al., 2008). Alternatively,
lymphoma cell lines bearing the ABC DLBCL-associated onco-
genic MYD88 signaling can also produce interferon b that signal
in an autocrine fashion through the type I interferon receptor to
activate classical interferon-response genes (Ngo et al., 2011).
At present, the adaptive benefit of interferon signaling to malig-
nant lymphoma cells is unclear because type I interferon is
typically antiproliferative and/or proapoptotic. Conceivably, the
immunomodulatory functions of interferon could help the tumor
evade immune surveillance. However, it is also possible that
interferon signaling is not a selected tumor phenotype but rather
the ‘‘price of doing business’’ with constitutive JAK activity in
lymphoma.
Recent data provide evidence that type II interferon signaling
pathway may play a role in myeloid disorders and that modula-
tion of its activity may be important in certain disease subtypes.
Historically, studying signaling downstream of mutant JAK2 in
primary cells from MPN patients has been challenging because
of interindividual variability in signaling pathway activity
combined with variable mixtures of mutant and normal cells.
This is reflected by the highly variable levels of tyrosine phos-
phorylated STAT5 or STAT3 in MPN patients that do not always
correlate with V617F allele burden (Aboudola et al., 2007;
Mesa et al., 2006; Teofili et al., 2007). Comparison of clonally
derived mutant and wild-type cells from each patient provides
a powerful way to circumvent these confounding variables.
Application of this strategy revealed unexpected cell-intrinsic
differences between PV and ET patients in the signaling
pathways activated by JAK2-V617F (Chen et al., 2010). STAT1
and its downstream transcriptional program were activated inImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 535
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but not in those from PV patients. This observation is likely to
reflect inherited or acquired genetic differences and may well
contribute to the phenotypic differences between ET and PV.
Extension of this approach to the study of other cancers is likely
to reveal unexpected complexity in the signaling consequences
of other oncogenic lesions.
PI3K-AKT Pathway
In addition to STAT proteins, JAKs can activate a variety of
additional signaling pathways. JAK2 can activate the phosphoi-
nositide 3-kinase (PI3K) by phosphorylating the erythropoietin
receptor (EPOR) on Y479, which causes recruitment of the
PI3K to the plasmamembrane where it activates AKT. Activation
of the PI3K-AKT signaling pathway is a feature of many
neoplasms associated with aberrant JAK signaling. It appears
to play a critical role in tumorigenesis, as shown by the fact
that fibroblasts coexpressing JAK2-V617F and an EPOR scaf-
fold unable to facilitate PI3K activation fail to form tumors
when transplanted into mice (Kamishimoto et al., 2011).
Increased PI3K-AKT signaling transforms cells by promoting
increased cell survival and proliferative index. Inhibition of PI3K
activity with pharmacological inhibitors reduces EEC formation
from PV progenitors, increases apoptosis of cells expressing
MPN- or ALL-associated JAK mutations, and reduces erythroid
proliferation (Funakoshi-Tago et al., 2009; Ugo et al., 2004).
These effects probably relate to the >100 nonredundant
substrates of AKT that have been identified. Upon phosphoryla-
tion, AKT targets are functionally inactivated by sequestration
either from essential protein partners or from their correct
subcellular compartments and many of these AKT targets are
known to be disrupted in mutant JAK-associated hematological
neoplasms: (1) inactivation of the proapoptotic protein BAD by
serine phosphorylation is a feature of JAK2-V617F-positive cell
lines (Gozgit et al., 2008); (2) inactivation of negative regulators
of mTORC1 increases ribosome biogenesis, mRNA translation,
and cell growth and proliferation, known features of JAK2-
V617F-positive MPNs (Lelie`vre et al., 2006)—indeed, the
mTORC1 inhibitor, rapamycin, has been demonstrated to be
cytotoxic for cell lines expressing many different oncogenic
JAK molecules (Li et al., 2010a); (3) increased phosphorylation
of glycogen synthase kinase 3b (GSK3b) promotes increased
cycling of PV erythroid progenitors by relieving inhibition of cyclin
D and E (Dai et al., 2005); and (4) inhibition of the forkhead box-
containing transcription factors (FOXO) family leads to impaired
activation of quiescence-associated genes and proapoptotic
genes. Although inactivation of FOXO members has yet to be
reported in malignancies associated with JAK mutations, it has
been implicated in disorders associated with elevated JAK-
STAT signaling such as CML and AML.
RAS-RAF1-MEK-ERK1 and -ERK2 Pathway
Oncogenic JAK molecules can also activate the RAS-RAF1-
MEK-ERK1 and -ERK2 cascade, the predominant mitogen-acti-
vated kinase (MAPK) pathway initiated by cytokine receptors.
In contrast to PI3K-AKT signaling, the contribution of ERK1
and ERK2 downstream of oncogenic JAK molecules seems to
be largely restricted to increased proliferative drive. MEK inhibi-
tors suppress S phase entry but not prosurvival signals in mutant536 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.JAK-expressing cells (Funakoshi-Tago et al., 2010; Ugo et al.,
2004). Consistent with this, elevated expression of ERK1 and
ERK2 targets JUNB and FOSB is seen in JAK2-V617F-positive
MPNs, and JUNB overexpression stimulates growth of erythroid
cells in vitro (da Costa Reis Monte-Mo´r et al., 2009; Puigdecanet
et al., 2008). Additional insights into the hematological conse-
quences of oncogenic RAS signaling have also been derived
from studies of juvenile myelomoncytic leukemia (JMML) and
chronic myelomonocytic leukemias (CMML). RAS or PTPN11
mutations account for 60% of JMMLs and 35% of CMMLs
(Loh, 2011). Both classes of mutations lead to dysregulated
signaling of the GM-CSF receptor, increased ERK1/2 activation,
and excessive monocyte production. Mice expressing a JMML-
associated mutation of K-Ras or N-Ras develop myeloprolifera-
tive disorders that closely resemble JMML or CMML with an
isolated expansion of mature monocytes but no erythroid or
lymphoid hyperplasia (Parikh et al., 2006). Although JAK2 is
bound to the GM-CSF receptor and is required for its signaling,
JAK2 mutations are rarely found in JMMLs. In addition, the few
patients with JAK-V617F-positive CMMLs rarely harbor RAS
mutations (Pe´rez et al., 2010).
Noncanonical Effects of Mutant JAK Signaling
In recent years, there has been mounting evidence for functions
of JAK molecules beyond their purview as adaptors in signal
transduction pathways. An early clue that JAKs may possess
additional functions was seen in Drosophila melanogaster where
constitutive JAK activation is associatedwith global disruption of
heterochromatic gene silencing in a fly leukemiamodel (Shi et al.,
2006). The mechanism by which JAK signaling modulates
heterochromatin stems from the unexpected observation that
JAK2 exists in the nucleus, where it directly phosphorylates the
histone H3 tail on tyrosine 41 (H3Y41) (Dawson et al., 2009).
Heterochromatin formation is associated with recruitment of
HP1a, which uses its carboxy-terminal chromo-shadow domain
to bind to this portion of the histone H3 tail in its unphosphory-
lated state. HP1a separately uses its amino-terminal chromo-
domain to interact with the heterochromatin mark H3K9me3.
H3Y41 phosphorylation leads to displacement of HP1a protein
from chromatin and increased gene transcription at that locus
(Dawson et al., 2009). The JAK2-H3Y41-HP1a signaling pathway
specifically targets thousands of loci, many of which lack identifi-
able STAT binding elements (Rui et al., 2010), and are thus likely
to activate an additional set of target genes distinct from those
regulated by canonical JAK-STAT signaling pathways. These
direct targets of nuclear JAK2 signaling are likely to have
functional roles in disease biology, as indicated by the fact that
phospho-Y41-mediated HP1a displacement can occur at loci
of proto-oncogenes (Dawson et al., 2009). Recently, this nonca-
nonical signaling pathway has been shown to be important in the
biology of lymphoma (Figure 3, bottom).
In addition to JAK2, two additional genes—JMJD2C and
RANBP6—situated within the HL/PMBL-associated 9p24
amplicon are known to be functionally important for tumor cell
proliferation and survival (Rui et al., 2010). No insights into
RANBP6 function have yet been provided in the scientific litera-
ture, although its inhibition potently reduced proliferation of
many PMBL and HL cell lines. JMJD2C is a chromatin-modifying
enzyme that demethylates trimethylated lysine 9 of the histone
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(Loh et al., 2007; Whetstine et al., 2006). Thus, JAK2-mediated
phosphorylation of H3Y41 and JMJD2C-mediated demethyla-
tion of H3K9me3 block both means of HP1a recruitment, poten-
tially accounting for the synergism between JAK2 and JMJD2C
in reducing heterochromatin formation in PMBL and HL. Conse-
quently, combined inhibition of JAK2 and JMJD2C in HL and
PMBL cells synergizes to increase heterochromatin and kill
PMBL and HL cell lines, demonstrating the functional coopera-
tion between these two amplicon genes (Rui et al., 2010).
Given that heterochromatin is typically associated with gene
silencing, the effects of JAK2 and JMJD2C on HP1a recruitment
positively regulate the expression of hundreds of genes in PMBL
and HL, several of which are likely to be involved in lymphoma
development: (1) MYC activation occurs through phosphoryla-
tion of the chromatin in the vicinity of the first intron of the
MYC locus and is functionally important in promoting survival
of PMBL and HL cells, although it is insufficient on its own to
mediate all of the prosurvival effects of nuclear JAK2 signaling
(Rui et al., 2010); (2) JAK2 and JMJD2C activation institutes
a positive feedforward regulatory loop (Rui et al., 2010); (3)
chromatin modification of IL4RA (which encodes an IL-13
receptor subunit) fosters autocrine IL-13 signaling (LaPorte
et al., 2008); and (4) increased expression of immunemodulators
PD-L1 and PD-L2 blocks T cell receptor signaling—because
PMBL and HL may arise amidst a sea of thymic T cells, such
negative regulation may be essential for the malignant clone to
escape immune surveillance (Rui et al., 2010).
These preclinical data provide a strong rationale for the clinical
evaluation of JAK2 inhibitors in PMBL and HL. JMJD2C also
emerges from these studies as an intriguing therapeutic target.
JMJD2C inhibitors could have single agent activity in PMBL
and HL and would be predicted to synergize with JAK2 inhibi-
tors. A concern when considering epigenetic regulators such
as JMJD2C as therapeutic targets is whether the side effects
of inhibitors will be tolerable. In this regard, it is notable that
reduced JMJD2C expression is not toxic for cell lines derived
from lymphoma subtypes other than PMBL and HL (Rui et al.,
2010). Thus, JMJD2C is not an essential gene in all cells,
meaning that a therapeutic window may exist for the clinical
development of JMJD2C inhibitors.
In summary, that JAK molecules have a noncanonical nuclear
function has been an unexpected finding and is suggesting
tantalizing links between the JAK-STAT pathway and hetero-
chromatin regulation in the pathogenesis of myeloid and
lymphoid malignancies. These observations may reflect a need
for cells to tightly regulate the chromatin state of their genome,
with dysregulation contributing to tumorigenesis. Further under-
standing of the role of these noncanonical pathways in disease
processes will aid in devising strategies to exploit these new
functions of JAK molecules for therapeutic intervention.
Clinical Implications
The discovery of JAK mutations has been rapidly translated into
the clinic. Arguably the most significant effect has been the
impact of JAK2 mutations on the diagnosis of MPNs, disorders
of which can be difficult to distinguish from reactive causes of
abnormal blood counts. Assays to detect the JAK2-V617F
mutation have greatly simplified diagnostic algorithms and theidentification of JAK2 exon 12 mutations have revealed the exis-
tence of a previously unrecognized subtype of PV (Scott et al.,
2007). JAK2 mutation testing is already firmly embedded in
national and international guidelines (Harrison et al., 2010;
McMullin et al., 2007; Tefferi and Vardiman, 2008).
Detection of JAK mutations is also beginning to provide
prognostic information. For example, in B precursor ALL, JAK
mutations are associated with a ‘‘high-risk’’ subgroup that
exhibits poor outcome (Mullighan et al., 2009b). Further decon-
volution of this high-risk cohort by gene expression profiling
shows the majority of JAK-mutated patients to be confined to
a subgroup that has exceedingly poor outcome (21% 4-year
relapse-free survival compared to 66% for the entire cohort)
(Harvey et al., 2010b), suggesting that these patients may repre-
sent candidates for more aggressive treatment regimens. Within
the MPNs, it has been suggested that the JAK2-V617F mutation
is associated with increased risk of thrombosis and/or leukemic
transformation (reviewed in Vannucchi et al., 2008).
Lastly, there is considerable interest in developing therapeutic
JAK inhibitors. In 2010, the results of the first clinical trials with
JAK kinase inhibitors for treatment of primary and post-PV and
ETmyelofibrosis were published (Santos et al., 2010; Verstovsek
et al., 2010). As reviewed elsewhere in this issue, multiple selec-
tive JAK2 inhibitors are now in early-phase trials and showing
promise in ameliorating symptoms in a subset of MPN patients.
Moreover, there are strong grounds for exploring the efficacy
of JAK inhibitors in multiple other hematological malignancies.
For example, JAK3 inhibition has recently been shown to be
effective in eradicating T cells from patients with adult T cell
leukemia or lymphoma in preclinical studies (Ju et al., 2011).
One point to emphasize is that clinical trials of JAK inhibitors
need not be confined to cases with JAKmutations. For example,
the gene expression signature of JAK2 activity is shared by most
PMBL tumors, with or without 9p24 amplification (Rui et al.,
2010), and MPN patients lacking a JAK2-V617F mutation
respond to selective JAK2 inhibition (Verstovsek et al., 2010).
However, these agents are limited by the toxic consequences
of inhibiting normal JAK2 and, at the moment, there is little
evidence that they alter the natural history of the MPNs. Thera-
peutic strategies that selectively target mutant proteins therefore
remain attractive, albeit challenging. In the future, deciphering
the complexities of mutant JAK signaling will facilitate identifica-
tion of new therapeutic targets and is also likely to lead to
improved approaches to stratified therapy.
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